Detailed explanation of usage and dosage of EPKINLY (icarelatumumab): ensuring maximum efficacy

EPKINLY (icarelatumumab) is a new bispecific antibody drug specifically used to treat relapsed or refractory diffuse largeB-cell lymphoma (DLBCL) and other Bcell lymphomas. In order to maximize its efficacy while reducing the risk of side effects, strict usage and dosage control is crucial.

EPKINLYFor subcutaneous injection only. This method of administration is more convenient than traditional intravenous injection and reduces the pain and inconvenience of patients. The injection site is usually selected in areas rich in subcutaneous fat such as the upper arms, thighs or abdomen, and is operated by professional medical personnel.

EPKINLY’s recommended dosage regimen has been carefully designed to balance efficacy and safety. The specific dosage is as follows:

Cycle 1: Adopt an ascending dose regimen to gradually enhance the patient's tolerance. Give 0.16mg on day 1 and give 0.8 on day 8 mg, 48 mg will be given on day 15 and day 22 respectively.

Cycles 2 to 3: The fixed weekly dose is 48mg, that is, in the One injection was given each on 1, 8, 15 and 22 days.

Cycles 4 to 9: The dosing frequency is adjusted to once every other week, that is, 48 mg will be administered on the 1 day and the 15 day.

The 10th cycle and beyond: the maintenance dose is once every four weeks, that is, 48 mg will be given on the 1 day.

In practical applications, doctors will make individual adjustments to the dosage based on the patient's specific conditions (such as age, weight, kidney function, disease severity, etc.) as well as treatment response and tolerance.

During treatment, patients need to undergo regular blood tests, imaging tests, etc. to evaluate the efficacy and monitor side effects. The doctor will adjust the treatment plan in a timely manner based on the monitoring results.

For pregnant women, lactating women, and patients with severe liver and kidney insufficiency, extreme caution is required when usingEPKINLY, and strict guidance from doctors must be followed.

EPKINLYMay interact with other drugs, affecting efficacy or increasing the risk of side effects. Therefore, during use, patients need to inform their doctors of all medications they are taking so that they can be evaluated and adjusted.

Reference materials:https://www.drugs.com/monograph/epcoritamab-bysp.html#dosage